About Us

Developing Targeted Therapies for Cancer

A Powerful Approach

Threshold is a biotechnology company focused on the discovery and development of therapeutics based on Tumor Hypoxia, a powerful scientific platform that offers broad potential to treat most solid tumors. By selectively targeting tumor cells, we are building a pipeline of drugs that hold promise to be more effective and less toxic to healthy tissues than conventional drugs.

Clinical Product Pipeline

TH-302 is a hypoxia-activated prodrug (HAP) for the potential treatment of solid tumors and some liquid tumors as well. TH-302, which was discovered at Threshold, is a novel drug candidate that is activated under the metabolic conditions typical of cancer cells. We started a Phase 1 clinical trial in July 2007 and, since then, have initiated several additional clinical trials of TH-302. The most advanced clinical is a Phase 2 multi-center, randomized, controlled, crossover clinical trial of TH-302 in combination with gemcitabine in patients with first line pancreatic cancer. We also plan to start a Phase 3 pivotal clinical trial of TH-302 in combination with doxorubicin in patients with soft tissue sarcoma.

A Significant Unmet Need

Our product candidates are focused on treating patients with significant unmet medical needs. Cancer is the second leading cause of death in the United States after cardiovascular disease. The American Cancer Society estimates that 569,490 people died from cancer in the United States in 2010. Many cancers, such as pancreatic, lung and liver cancer, have few effective treatments and very low survival rates.